Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors

a retrospective multicenter study

Pejman Ghanouni, Andrew Dobrotwir, Alberto Bazzocchi, Matthew Bucknor, Rachelle Bitton, Jarrett Rosenberg, Kristen Telischak, Maurizio Busacca, Stefano Ferrari, Ugo Albisinni, Shannon Walters, Garry Gold, Kristen Ganjoo, Alessandro Napoli, Kim Butts Pauly, Raffi Avedian

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives: To assess the feasibility, safety and preliminary efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of extra-abdominal desmoid tumours. Methods: Fifteen patients with desmoid fibromatosis (six males, nine females; age range, 7–66 years) were treated with MRgFUS, with seven patients requiring multiple treatments (25 total treatments). Changes in viable and total tumour volumes were measured after treatment. Efficacy was evaluated using an exact one-sided Wilcoxon test to determine if the median reduction in viable tumour measured immediately after initial treatment exceeded a threshold of 50 % of the targeted volume. Median decrease after treatment of at least two points in numerical rating scale (NRS) worst and average pain scores was tested with an exact one-sided Wilcoxon test. Adverse events were recorded. Results: After initial MRgFUS treatment, median viable targeted tumour volume decreased 63 %, significantly beyond our efficacy threshold (P = 0.0013). Median viable total tumour volume decreased (105 mL [interquartile range {IQR}, 217 mL] to 54 mL [IQR, 92 mL]) and pain improved (worst scores, 7.5 ± 1.9 vs 2.7 ± 2.6, P = 0.027; average scores, 6 ± 2.3 vs 1.3 ± 2, P = 0.021). Skin burn was the most common complication. Conclusions: MRgFUS significantly and durably reduced viable tumour volume and pain in this series of 15 patients with extra-abdominal desmoid fibromatosis. Key Points: • Retrospective four-centre study shows MRgFUS safely and effectively treats extra-abdominal desmoid tumours• This non-invasive procedure can eradicate viable tumour in some cases• Alternatively, MRgFUS can provide durable control of tumour growth through repeated treatments• Compared to surgery or radiation, MRgFUS has relatively mild side effects

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalEuropean Radiology
DOIs
Publication statusAccepted/In press - May 5 2016

Fingerprint

Aggressive Fibromatosis
Multicenter Studies
Magnetic Resonance Spectroscopy
Retrospective Studies
Tumor Burden
Neoplasms
Therapeutics
Pain
Abdominal Fibromatosis
Fibroma
Radiation
Safety
Skin

Keywords

  • Desmoid fibromatosis
  • High-intensity focused ultrasound (HIFU)
  • MR-guided focused ultrasound
  • MRgFUS
  • Thermal ablation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors : a retrospective multicenter study. / Ghanouni, Pejman; Dobrotwir, Andrew; Bazzocchi, Alberto; Bucknor, Matthew; Bitton, Rachelle; Rosenberg, Jarrett; Telischak, Kristen; Busacca, Maurizio; Ferrari, Stefano; Albisinni, Ugo; Walters, Shannon; Gold, Garry; Ganjoo, Kristen; Napoli, Alessandro; Pauly, Kim Butts; Avedian, Raffi.

In: European Radiology, 05.05.2016, p. 1-9.

Research output: Contribution to journalArticle

Ghanouni, P, Dobrotwir, A, Bazzocchi, A, Bucknor, M, Bitton, R, Rosenberg, J, Telischak, K, Busacca, M, Ferrari, S, Albisinni, U, Walters, S, Gold, G, Ganjoo, K, Napoli, A, Pauly, KB & Avedian, R 2016, 'Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study', European Radiology, pp. 1-9. https://doi.org/10.1007/s00330-016-4376-5
Ghanouni, Pejman ; Dobrotwir, Andrew ; Bazzocchi, Alberto ; Bucknor, Matthew ; Bitton, Rachelle ; Rosenberg, Jarrett ; Telischak, Kristen ; Busacca, Maurizio ; Ferrari, Stefano ; Albisinni, Ugo ; Walters, Shannon ; Gold, Garry ; Ganjoo, Kristen ; Napoli, Alessandro ; Pauly, Kim Butts ; Avedian, Raffi. / Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors : a retrospective multicenter study. In: European Radiology. 2016 ; pp. 1-9.
@article{1619a78dd1db4886bd2a825f997af51d,
title = "Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study",
abstract = "Objectives: To assess the feasibility, safety and preliminary efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of extra-abdominal desmoid tumours. Methods: Fifteen patients with desmoid fibromatosis (six males, nine females; age range, 7–66 years) were treated with MRgFUS, with seven patients requiring multiple treatments (25 total treatments). Changes in viable and total tumour volumes were measured after treatment. Efficacy was evaluated using an exact one-sided Wilcoxon test to determine if the median reduction in viable tumour measured immediately after initial treatment exceeded a threshold of 50 {\%} of the targeted volume. Median decrease after treatment of at least two points in numerical rating scale (NRS) worst and average pain scores was tested with an exact one-sided Wilcoxon test. Adverse events were recorded. Results: After initial MRgFUS treatment, median viable targeted tumour volume decreased 63 {\%}, significantly beyond our efficacy threshold (P = 0.0013). Median viable total tumour volume decreased (105 mL [interquartile range {IQR}, 217 mL] to 54 mL [IQR, 92 mL]) and pain improved (worst scores, 7.5 ± 1.9 vs 2.7 ± 2.6, P = 0.027; average scores, 6 ± 2.3 vs 1.3 ± 2, P = 0.021). Skin burn was the most common complication. Conclusions: MRgFUS significantly and durably reduced viable tumour volume and pain in this series of 15 patients with extra-abdominal desmoid fibromatosis. Key Points: • Retrospective four-centre study shows MRgFUS safely and effectively treats extra-abdominal desmoid tumours• This non-invasive procedure can eradicate viable tumour in some cases• Alternatively, MRgFUS can provide durable control of tumour growth through repeated treatments• Compared to surgery or radiation, MRgFUS has relatively mild side effects",
keywords = "Desmoid fibromatosis, High-intensity focused ultrasound (HIFU), MR-guided focused ultrasound, MRgFUS, Thermal ablation",
author = "Pejman Ghanouni and Andrew Dobrotwir and Alberto Bazzocchi and Matthew Bucknor and Rachelle Bitton and Jarrett Rosenberg and Kristen Telischak and Maurizio Busacca and Stefano Ferrari and Ugo Albisinni and Shannon Walters and Garry Gold and Kristen Ganjoo and Alessandro Napoli and Pauly, {Kim Butts} and Raffi Avedian",
year = "2016",
month = "5",
day = "5",
doi = "10.1007/s00330-016-4376-5",
language = "English",
pages = "1--9",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors

T2 - a retrospective multicenter study

AU - Ghanouni, Pejman

AU - Dobrotwir, Andrew

AU - Bazzocchi, Alberto

AU - Bucknor, Matthew

AU - Bitton, Rachelle

AU - Rosenberg, Jarrett

AU - Telischak, Kristen

AU - Busacca, Maurizio

AU - Ferrari, Stefano

AU - Albisinni, Ugo

AU - Walters, Shannon

AU - Gold, Garry

AU - Ganjoo, Kristen

AU - Napoli, Alessandro

AU - Pauly, Kim Butts

AU - Avedian, Raffi

PY - 2016/5/5

Y1 - 2016/5/5

N2 - Objectives: To assess the feasibility, safety and preliminary efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of extra-abdominal desmoid tumours. Methods: Fifteen patients with desmoid fibromatosis (six males, nine females; age range, 7–66 years) were treated with MRgFUS, with seven patients requiring multiple treatments (25 total treatments). Changes in viable and total tumour volumes were measured after treatment. Efficacy was evaluated using an exact one-sided Wilcoxon test to determine if the median reduction in viable tumour measured immediately after initial treatment exceeded a threshold of 50 % of the targeted volume. Median decrease after treatment of at least two points in numerical rating scale (NRS) worst and average pain scores was tested with an exact one-sided Wilcoxon test. Adverse events were recorded. Results: After initial MRgFUS treatment, median viable targeted tumour volume decreased 63 %, significantly beyond our efficacy threshold (P = 0.0013). Median viable total tumour volume decreased (105 mL [interquartile range {IQR}, 217 mL] to 54 mL [IQR, 92 mL]) and pain improved (worst scores, 7.5 ± 1.9 vs 2.7 ± 2.6, P = 0.027; average scores, 6 ± 2.3 vs 1.3 ± 2, P = 0.021). Skin burn was the most common complication. Conclusions: MRgFUS significantly and durably reduced viable tumour volume and pain in this series of 15 patients with extra-abdominal desmoid fibromatosis. Key Points: • Retrospective four-centre study shows MRgFUS safely and effectively treats extra-abdominal desmoid tumours• This non-invasive procedure can eradicate viable tumour in some cases• Alternatively, MRgFUS can provide durable control of tumour growth through repeated treatments• Compared to surgery or radiation, MRgFUS has relatively mild side effects

AB - Objectives: To assess the feasibility, safety and preliminary efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of extra-abdominal desmoid tumours. Methods: Fifteen patients with desmoid fibromatosis (six males, nine females; age range, 7–66 years) were treated with MRgFUS, with seven patients requiring multiple treatments (25 total treatments). Changes in viable and total tumour volumes were measured after treatment. Efficacy was evaluated using an exact one-sided Wilcoxon test to determine if the median reduction in viable tumour measured immediately after initial treatment exceeded a threshold of 50 % of the targeted volume. Median decrease after treatment of at least two points in numerical rating scale (NRS) worst and average pain scores was tested with an exact one-sided Wilcoxon test. Adverse events were recorded. Results: After initial MRgFUS treatment, median viable targeted tumour volume decreased 63 %, significantly beyond our efficacy threshold (P = 0.0013). Median viable total tumour volume decreased (105 mL [interquartile range {IQR}, 217 mL] to 54 mL [IQR, 92 mL]) and pain improved (worst scores, 7.5 ± 1.9 vs 2.7 ± 2.6, P = 0.027; average scores, 6 ± 2.3 vs 1.3 ± 2, P = 0.021). Skin burn was the most common complication. Conclusions: MRgFUS significantly and durably reduced viable tumour volume and pain in this series of 15 patients with extra-abdominal desmoid fibromatosis. Key Points: • Retrospective four-centre study shows MRgFUS safely and effectively treats extra-abdominal desmoid tumours• This non-invasive procedure can eradicate viable tumour in some cases• Alternatively, MRgFUS can provide durable control of tumour growth through repeated treatments• Compared to surgery or radiation, MRgFUS has relatively mild side effects

KW - Desmoid fibromatosis

KW - High-intensity focused ultrasound (HIFU)

KW - MR-guided focused ultrasound

KW - MRgFUS

KW - Thermal ablation

UR - http://www.scopus.com/inward/record.url?scp=84965038825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965038825&partnerID=8YFLogxK

U2 - 10.1007/s00330-016-4376-5

DO - 10.1007/s00330-016-4376-5

M3 - Article

SP - 1

EP - 9

JO - European Radiology

JF - European Radiology

SN - 0938-7994

ER -